BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28881753)

  • 1. siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells.
    Yuan HH; Yang YN; Zhou JH; Li YJ; Wang LY; Qin JW; Liu T; Li ZZ; Zhou QX; Wei XL; Zhang TT; Huang P; Zhang WJ; Liu L; Du XX; Han Y
    Oncotarget; 2017 Aug; 8(32):52584-52593. PubMed ID: 28881753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER3 signaling and targeted therapy in cancer.
    Mishra R; Patel H; Alanazi S; Yuan L; Garrett JT
    Oncol Rev; 2018 Jan; 12(1):355. PubMed ID: 30057690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
    Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
    Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinib.
    Wang L; Zhang H; Zheng J; Wei X; Du J; Lu H; Sun Q; Zhou W; Zhang R; Han Y
    Mol Carcinog; 2018 Aug; 57(8):1008-1016. PubMed ID: 29637613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
    Djerf EA; Trinks C; Abdiu A; Thunell LK; Hallbeck AL; Walz TM
    Melanoma Res; 2009 Jun; 19(3):156-66. PubMed ID: 19434003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
    Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
    J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
    Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
    Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
    Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
    Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
    Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
    Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
    Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
    Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
    Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).
    Schoeberl B; Kudla A; Masson K; Kalra A; Curley M; Finn G; Pace E; Harms B; Kim J; Kearns J; Fulgham A; Burenkova O; Grantcharova V; Yarar D; Paragas V; Fitzgerald J; Wainszelbaum M; West K; Mathews S; Nering R; Adiwijaya B; Garcia G; Kubasek B; Moyo V; Czibere A; Nielsen UB; MacBeath G
    NPJ Syst Biol Appl; 2017; 3():16034. PubMed ID: 28725482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.
    Ono M; Kuwano M
    Clin Cancer Res; 2006 Dec; 12(24):7242-51. PubMed ID: 17189395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
    Segovia-Mendoza M; Díaz L; González-González ME; Martínez-Reza I; García-Quiroz J; Prado-Garcia H; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; García-Becerra R
    J Steroid Biochem Mol Biol; 2015 Apr; 148():122-31. PubMed ID: 25510900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
    Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
    Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER1-4 expression status correlates with the efficacy of gefitinib treatment and tumor cell proliferative activity in non-small cell lung cancer.
    Fujita M; Ishida M; Tezuka N; Fujino S; Asai T; Okabe H
    Mol Med Rep; 2008; 1(2):225-30. PubMed ID: 21479401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.